SCHEMBL20101541

SCHEMBL20101541

COc1cnc(Cl)nc1OCC[Si](C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PIN1 Q13526 5/20 0.39
GAA P10253 1/20 0.36
NUDT1 P36639 1/20 0.35
KMT2A Q03164 3/20 0.34
TNF P01375 1/20 0.34
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 4/20 0.32
MAPT P10636 3/20 0.32
CYP1A2 P05177 3/20 0.32
MEN1 O00255 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2D6 P10635 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HTT P42858 1/20 0.32
POLB P06746 2/20 0.32
PLA2G1B P04054 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393577 0.80 RXRA (0.38) ALDH1A1KDM4ESMN1; SMN2PIN1NUDT1
SCHEMBL23836782 0.79 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL19907125 0.79 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL20101545 0.79 MEN1 (0.34) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL31533165 0.79 MEN1 (0.34) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL2437490 0.79 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL30786798 0.79 ALDH1A1 (0.53) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL24529613 0.78 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2PIN1GAA
SCHEMBL24387164 0.76 LMNA (0.35) ALDH1A1KDM4ESMN1; SMN2NUDT1KMT2A
SCHEMBL24386913 0.76 NUDT1 (0.35) SMN1; SMN2NUDT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116600803-A Macrocyclic urea orexin receptor agonists 默沙东有限责任公司 2023-08-15 CN disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 WO disclosed
WO-2022094012-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-05 WO disclosed
US-20210292283-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2021-09-23 US disclosed
US-10774051-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2020-09-15 US disclosed
US-9988373-B2 Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2018-06-05 US disclosed
US-9988373-B2 Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2018-06-05 US disclosed
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S ALDH1A1 2484/4885KDM4E 2157/4885SMN1; SMN2 3478/4885
US-20210292283-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S ALDH1A1 2195/4885KDM4E 2170/4885SMN1; SMN2 3496/4885
US-10774051-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S ALDH1A1 2484/4885KDM4E 2157/4885SMN1; SMN2 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.